Pulse Biosciences’ Nanosecond Pulsed Field Ablation (nsPFA™) Circumferential Catheter System to be Featured in a Presentation at the Global EP Summit
September 29 2023 - 8:00AM
Business Wire
Pulse Biosciences, Inc. (Nasdaq: PLSE, “the Company”), a company
primarily focused on leveraging its novel and proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology for the
treatment of atrial fibrillation, today announced its nsPFA
technology will be featured in a presentation at the Global EP
Summit 2023 in Cleveland, OH from September 29th to 30th, 2023.
“I believe Pulse Biosciences’ nsPFA circumferential catheter
system represents a novel and highly differentiated solution for
the treatment of atrial fibrillation by electrophysiologists.
Consistently performing circumferential ablations of targeted
pulmonary veins in a single shot, in approximately 5 seconds with
nsPFA, not only represents a significant time advantage, but also a
simpler procedure that could lead to improved patient outcomes,”
said Dr. Usman Siddiqui, Chief of Electrophysiology at Advent
Health, Director of EP at Advent/Nicholson Center, Associate
Professor of Medicine University of Central Florida. “I look
forward to detailing both the utility of the novel energy modality
and its potential impact on the treatment of AF with fellow EPs at
the Global EP Summit.”
Presentation Details: Next Generation PFA Dr. Usman R.
Siddiqui September 29, 2023 from 8:20 am – 8:30 am ET
During this presentation, Dr. Usman Siddiqui will be discussing
Pulse Biosciences’ nsPFA technology and catheter system.
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company
committed to health innovation that has the potential to improve
the quality of life for patients. The Company’s proprietary
Nanosecond Pulsed Field Ablation (nsPFA) technology delivers
nanosecond pulses of electrical energy to non-thermally clear cells
while sparing adjacent noncellular tissue. The Company is actively
pursuing the development of its nsPFA technology for use in the
treatment of atrial fibrillation and in a select few other markets
where nsPFA could have a profound positive impact on healthcare for
both patients and providers.
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA
and the stylized logos are among the trademarks and/or registered
trademarks of Pulse Biosciences, Inc. in the United States and
other countries.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230929523434/en/
Investor Contacts: Pulse Biosciences Kevin Danahy,
President and CEO 510.241.1077 IR@pulsebiosciences.com
or
Gilmartin Group Philip Trip Taylor 415.937.5406
philip@gilmartinir.com
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Jul 2024 to Aug 2024
Pulse Biosciences (NASDAQ:PLSE)
Historical Stock Chart
From Aug 2023 to Aug 2024